spironolactone has been researched along with Aortic Stenosis in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study is to determine whether the selective aldosterone-receptor antagonist eplerenone delays onset of left ventricular (LV) systolic dysfunction or reduces LV hypertrophy in asymptomatic patients with moderate to severe aortic stenosis." | 9.13 | A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. ( Cowan, BR; Doughty, RN; Edwards, C; Freidlander, D; Kerr, AJ; Occleshaw, C; Richards, AM; Stewart, RA; Whalley, GA; White, HD; Williams, M; Young, AA; Zeng, I, 2008) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 7.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 7.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| "The aim of the study is to determine whether the selective aldosterone-receptor antagonist eplerenone delays onset of left ventricular (LV) systolic dysfunction or reduces LV hypertrophy in asymptomatic patients with moderate to severe aortic stenosis." | 5.13 | A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. ( Cowan, BR; Doughty, RN; Edwards, C; Freidlander, D; Kerr, AJ; Occleshaw, C; Richards, AM; Stewart, RA; Whalley, GA; White, HD; Williams, M; Young, AA; Zeng, I, 2008) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 3.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 3.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajimoto, K | 1 |
| Otsubo, S | 1 |
| Okoshi, MP | 1 |
| Cezar, MDM | 1 |
| Iyomasa, RM | 1 |
| Silva, MB | 1 |
| Costa, LCO | 1 |
| Martinez, PF | 1 |
| Campos, DHS | 1 |
| Damatto, RL | 1 |
| Minicucci, MF | 1 |
| Cicogna, AC | 1 |
| Okoshi, K | 1 |
| Stewart, RA | 1 |
| Kerr, AJ | 1 |
| Cowan, BR | 1 |
| Young, AA | 1 |
| Occleshaw, C | 1 |
| Richards, AM | 1 |
| Edwards, C | 1 |
| Whalley, GA | 1 |
| Freidlander, D | 1 |
| Williams, M | 1 |
| Doughty, RN | 1 |
| Zeng, I | 1 |
| White, HD | 1 |
| Ramaraj, R | 1 |
| Marciniak, TA | 1 |
| Pocock, SJ | 1 |
| Ariti, CA | 1 |
| Collier, TJ | 1 |
| Wang, D | 1 |
| Jolobe, OM | 2 |
| Bang, CN | 1 |
| Greve, AM | 1 |
| Wachtell, K | 1 |
| Kober, L | 1 |
| Perrier, E | 1 |
| Kerfant, BG | 1 |
| Lalevee, N | 1 |
| Bideaux, P | 1 |
| Rossier, MF | 1 |
| Richard, S | 1 |
| Gómez, AM | 1 |
| Benitah, JP | 1 |
| Valentin, N | 1 |
| Olesen, KH | 1 |
| Eriksson, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289] | Phase 3 | 147 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to DSMB advise due to high probability of futility) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Aortic Stenosis
| Article | Year |
|---|---|
Evolving strategies for the use of spironolactone in cardiovascular disease.
Topics: Aortic Valve Stenosis; Diuretics; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Ant | 2013 |
1 trial available for spironolactone and Aortic Stenosis
| Article | Year |
|---|---|
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Blood Flow Velocity; Echocardiography, Doppler; Eplerenone; Female; Hum | 2008 |
10 other studies available for spironolactone and Aortic Stenosis
| Article | Year |
|---|---|
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; | 2019 |
Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload.
Topics: Aldosterone; Animals; Aortic Valve Stenosis; Cardiomegaly; Electrocardiography; Male; Mineralocortic | 2016 |
Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
Topics: Aortic Valve Stenosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Spiron | 2009 |
Eplerenone treatment of aortic stenosis. [letter].
Topics: Aortic Valve Stenosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Spiron | 2009 |
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; | 2012 |
A therapeutic opportunity that needs to be optimized.
Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplereno | 2012 |
Global systolic load, left ventricular hypertrophy, and atrial fibrillation.
Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplereno | 2012 |
Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction.
Topics: Action Potentials; Animals; Aorta, Abdominal; Aortic Valve Stenosis; Calcium; Calcium Channels, L-Ty | 2004 |
Muscle electrolytes and total exchangeable electrolytes in patients with cardiac diseases.
Topics: Adult; Age Factors; Aortic Valve Stenosis; Body Water; Chlorides; Cytoplasm; Digoxin; Diuretics; Ext | 1973 |
Severe hypernatremia complicating heart valve surgery. A preliminary report.
Topics: Aortic Valve; Aortic Valve Stenosis; Body Weight; Chlorides; Heart Failure; Heart Valve Prosthesis; | 1969 |